Merck (MRK) Change in Accured Expenses (2009)

Merck (MRK) reported Change in Accured Expenses of $448.0 million for Q4 2009, up 667.09% quarter-over-quarter from -$79.0 million in Q3 2009.

Merck (MRK) Change in Accured Expenses (2009) Analysis & Trends

Merck (MRK) has 1 years of Change in Accured Expenses data on file, last reported at $448.0 million in Q4 2009.

Change in Accured Expenses for Q4 2009 came in at $448.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2009 was -$910.0 million (changed N/A YoY), and the FY2025 annual result was -$1.8 billion, down 3657.14% from the prior year.
Change in Accured Expenses improved to $448.0 million in Q4 2009 per MRK's latest filing, from -$79.0 million in the prior quarter.
Over five years, Change in Accured Expenses peaked at $448.0 million in Q4 2009 and troughed at -$79.0 million in Q3 2009.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Accured Expenses (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn	-
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn	-
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn	-629.00 Mn
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn	-1.59 Bn
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn	-
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn	-75.00 Mn
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn	-702.00 Mn
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn	-
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn	-3.50 Bn
10	Novartis Ag	108.28 Bn	107.60 Bn	-	-

Download Data